Inflammation plays a pivotal role in atherogenesis. In addition to being a potent predictive and prognostic marker for major cardiovascular events,recent evidence indicates that C-reactive protein (CRP) might directly promote atherogenesis by exerting direct effects on vascular cells. Thus,CRP will become important novel pharmaceutical targets for the treatment of atherosclerosis. This review presents an overview of the current knowledge about the pathological role of CRP in atherosclerosis initiation and progression.
目的将GPR109A基因插入pEGFP-N3载体中构建重组质粒pEGFP-GPR109A,并建立稳定表达烟酸受体GPR109A的中国仓鼠卵巢(Ch inese ham ster ovary,CHO)细胞株。方法构建重组质粒pEGFP-GPR109A,重组质粒转化大肠杆菌DH5 a,重组质粒经PCR、酶切、测序验证正确后,应用脂质体转染技术将该质粒导入CHO细胞,用抗生素G418筛选稳定表达的细胞。倒置荧光显微镜观察克隆细胞株荧光信号,RT-PCR检测GPR109A基因mRNA表达,W estern B lotting检测绿色荧光蛋白与烟酸受体GPR109A的融合蛋白(GFP-GPR109A)的表达,激光共聚焦显微镜观察融合蛋白的细胞定位。结果 pEGFP-GPR109A真核表达质粒构建正确,融合蛋白GFP-GPR109A在CHO细胞中稳定表达,表达的融合蛋白主要定位于细胞膜。结论成功构建pEGFP-GPR109A真核表达载体并建立其稳定表达的CHO细胞株;该细胞株的建立有助于GPR109A的更多生理病理功能研究,也为下一步抗动脉粥样硬化的药物筛选奠定了基础。
